Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Activating mutations of SHP2 have been reported as a cause of various human diseases such as solid tumors, leukemia, and Noonan syndrome.
|
31784318 |
2020 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In addition, the mutation rate for SHP2 is the highest for colorectal cancer (CRC) among solid tumors.
|
29323748 |
2018 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Shp2 (Src-homology 2 domain-containing phosphatase 2) was originally reported as an oncogene in kinds of solid tumors and hematologic malignancies.
|
28085101 |
2017 |
Solid Neoplasm
|
0.400 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Germline Genetic Predisposition to Hematologic Malignancy.
|
28297620 |
2017 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Gain-of-function (GOF) mutations of protein tyrosine phosphatase nonreceptor type 11 Ptpn11 (Shp2), a protein tyrosine phosphatase implicated in multiple cell signaling pathways, are associated with childhood leukemias and solid tumors.
|
26755576 |
2016 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Germline and somatic mutations in PTPN11 are involved in Noonan syndrome (NS), LEOPARD syndrome (LS), and hematological malignancies, as well as several solid tumors.
|
25039348 |
2014 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we report that induction of the Ptpn11(E76K/+) mutation, the most common and active Ptpn11 mutation found in leukemias and solid tumors, in primary mouse embryonic fibroblasts resulted in proliferative arrest and premature senescence.
|
23884424 |
2013 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Gain-of-function SHP2 mutations are associated with Noonan syndrome, various kinds of leukemias, and solid tumors.
|
20170098 |
2010 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The association of this p.G60A PTPN11 mutation with neuroblastoma provides new evidence that gain of function PTPN11 mutations may play an important role in the pathogenesis of solid tumors associated with Noonan syndrome.
|
18328949 |
2008 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Although rare in solid tumors, the identified T507K SHP-2 represents a distinct class of SHP-2 mutants with oncogenic RAS-like transforming activity, which could contribute to the development of solid tumors.
|
18223690 |
2008 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We now know that at least one other PTP, the SH2 domain-containing phosphatase Shp2, is a bona fide oncogene that is mutated in several types of leukemia and hyperactivated by other mechanisms in some solid tumors.
|
17227708 |
2007 |
Solid Neoplasm
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we screened a number of solid tumors, including those documented in NS or in which deregulated RAS signaling occurs at significant frequency, for PTPN11 mutations.
|
16631468 |
2006 |